Is Fulgent Genetics a Good Healthcare Stock to Buy?

·2 min read

While it's natural to track share prices of your favorite stocks, it's important to remember that price alone never indicates a good or bad stock. This is despite the fact that the stock reported excellent third-quarter earnings on Nov. 9 with its core revenue up nearly 300% year over year and total revenue up 124% from the year-ago period. In this segment of Backstage Pass, recorded on Nov. 5, Fool contributors Toby Bordelon and Rachel Warren respond to a viewer's question about the stock and its volatile share price lately.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting